– Company Also Announces Participation in the
BTIG Biotechnology Conference and the Stifel Biotech Summer Summit
–
SEATTLE, Aug. 1, 2022
/PRNewswire/ -- CTI BioPharma Corp. (CTI
BioPharma) (NASDAQ: CTIC) today
announced that management plans to report its second quarter 2022
financial results on Monday, August 8,
2022, after the close of the U.S. financial markets.
Following the announcement, members of the management team will
host a conference call and webcast to discuss the results and
provide a general corporate update at 4:30
p.m. ET (1:30 p.m.
PT).
To access the live call by phone please dial (888) 317-6003
(domestic) or (412) 317-6061 (international); the conference ID is
0078819. A live audio webcast of the event may also be accessed
through the "Investors" section of CTI's website at
www.ctibiopharma.com. A replay of the webcast will be available for
30 days following the event.
August Conferences
CTI BioPharma also announced that
it will participate in one-on-one meetings at the BTIG
Biotechnology Conference on August 9,
2022. Additionally, the Company will participate in a
fireside chat and one-on-one meetings at the Stifel Biotech Summer
Summit on Tuesday, August 16, 2022,
at 11:00 am E.T.
The Stifel fireside chat will be webcast live and available for
replay from the Investors section of CTI BioPharma's website at
www.ctibiopharma.com.
About CTI BioPharma Corp.
We are a commercial
biopharmaceutical company focused on the acquisition, development
and commercialization of novel targeted therapies for blood-related
cancers that offer a unique benefit to patients and their
healthcare providers. CTI has one FDA-approved product
VONJO® (pacritinib), a JAK2 and IRAK1, that spares JAK1.
VONJO is approved for the treatment of adults with intermediate or
high-risk primary or secondary (post-polycythemia vera or
post-essential thrombocythemia) myelofibrosis with a platelet count
below 50 × 109/L. This indication is approved under FDA
accelerated approval based on spleen volume reduction. Continued
approval for this indication may be contingent upon verification
and description of clinical benefit in a confirmatory trial(s). CTI
is conducting the Phase 3 PACIFICA study of VONJO in patients with
myelofibrosis and severe thrombocytopenia as a post-marketing
requirement.
VONJO® is a registered trademark of CTI BioPharma
Corp.
CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-report-second-quarter-2022-financial-results-on-august-8-2022-301596903.html
SOURCE CTI BioPharma Corp.